On May 9 a woman filed a lawsuit against drug makers Amylin Pharmaceuticals and Eli Lilly in federal court, alleging that the companies failed to adequately warn her about type 2 diabetes drug Byetta’s link to thyroid cancer, according to court documents for Childress v. Amylin Pharmaceuticals LLC, et al., No. 3:13-1114 (U.S. District Court for the Southern District of California). The Rottenstein Law Group LLP maintains a Byetta Lawsuits Center at http://www.byettalawsuits.us, which features comprehensive information about the drug and steps that need to be taken to file a lawsuit.
Elizabeth Childress was prescribed Byetta in January 2007 to treat her type 2 diabetes, and continued to take it through August of that year, according to court documents. In May 2011 she was diagnosed with thyroid cancer and attributes it to her use of Byetta, a drug that has also been linked to both thyroid cancer and pancreatic cancer in women.* Childress alleges that the drug makers were aware of the risks but did not notify patients of them.
“It is important that the drug makers are held accountable, if the allegations are true,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP.
Read more: Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports